Efficacy of Phosphodiesterase Type 5 Inhibitors in Univentricular Congenital Heart Disease: The SV-INHIBITION Study Design

Abstract

The SV-INHIBITION study aims to answer the question whether PDE5 inhibitors should be prescribed in patients with an SV. This trial has been built focusing on the three levels of research defined by the World Health Organization: disability (exercise tolerance), deficit (SV function), and handicap (quality of life).